Yang, Sherry X <br/><br/>
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jun 2010 
 - 2974-81 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2009.26.1602  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Cyclophosphamide--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunoenzyme Techniques<br/>Lymph Nodes--metabolism<br/>Lymphatic Metastasis<br/>Middle Aged<br/>Neoplasm Staging<br/>Paclitaxel--administration & dosage<br/>Phosphorylation<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--metabolism<br/>Receptors, Progesterone--metabolism<br/>Serine--chemistry<br/>Tissue Array Analysis<br/>Treatment Outcome